Insmed (INSM) Expected to Announce Quarterly Earnings on Thursday

Insmed (NASDAQ:INSM) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of ($1.25) per share and revenue of $263.9660 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 19, 2026 at 8:00 AM ET.

Insmed Price Performance

Shares of INSM stock opened at $148.75 on Tuesday. Insmed has a 12-month low of $60.40 and a 12-month high of $212.75. The firm has a market capitalization of $31.72 billion, a price-to-earnings ratio of -24.03 and a beta of 1.11. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The firm has a fifty day moving average of $168.10 and a 200-day moving average of $162.59.

Analyst Ratings Changes

INSM has been the subject of a number of research analyst reports. Roth Mkm raised Insmed to a “strong-buy” rating in a research note on Friday, January 23rd. Mizuho set a $212.00 price objective on Insmed in a report on Thursday, December 18th. Wolfe Research set a $167.00 price objective on Insmed and gave the company an “outperform” rating in a research report on Thursday, December 18th. Morgan Stanley raised their target price on shares of Insmed from $157.00 to $162.00 and gave the stock an “equal weight” rating in a report on Friday, January 30th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Insmed presently has an average rating of “Buy” and an average price target of $204.24.

Insider Buying and Selling at Insmed

In other news, COO Roger Adsett sold 791 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total transaction of $123,530.47. Following the completion of the transaction, the chief operating officer directly owned 106,810 shares in the company, valued at $16,680,517.70. This represents a 0.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael Alexander Smith sold 640 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.27, for a total value of $100,012.80. Following the completion of the transaction, the insider owned 56,397 shares of the company’s stock, valued at $8,813,159.19. The trade was a 1.12% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 173,253 shares of company stock valued at $29,629,842 over the last quarter. 3.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC boosted its holdings in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the last quarter. Raiffeisen Bank International AG bought a new stake in Insmed during the fourth quarter worth $32,000. Towarzystwo Funduszy Inwestycyjnych PZU SA bought a new stake in Insmed during the fourth quarter worth $49,000. Transamerica Financial Advisors LLC lifted its stake in Insmed by 72.3% in the fourth quarter. Transamerica Financial Advisors LLC now owns 348 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 146 shares during the last quarter. Finally, Johnson Financial Group Inc. bought a new position in shares of Insmed in the 3rd quarter valued at about $67,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.